Developed over the last two decades, it has shown to be effective in treating multiple cancers, including breast and prostate.
Scientists at a leading US hospital have developed a “cancer-killing pill” that kills solid tumours through “targeted chemotherapy.” Likened to a “snowstorm that closes a key airline hub, shutting down all flights in and out only in planes carrying cancer cells”, the protein was developed by a research team at the City of Hope, one of the largest cancer research and treatment organisations in the US.
Developed over the last two decades, it has shown to be effective in preclinical research treating breast, prostate, brain, ovarian, cervical, skin and lung cancers. The study, has tested the protein across over 70 cancer cell lines.
Background -
PCNA - Proliferating Cell Nuclear Antigen plays an essential role in nucleic acid metabolism as a component of the replication and repair machinery. This toroidal-shaped protein encircles DNA and can slide bidirectionally along the duplex. It has been historically used as a marker for tumor progression. DNA replication stress is a key hallmark of cancer cells that have been exploited as a therapeutic strategy to induce further DNA damage leading to catastrophic consequences for cancer cells. Thus, PCNA represents a major anti-cancer target, given its role in DNA replication/repair. Besides, discovering a distinct cancer-associated PCNA isoform (caPCNA) has opened new avenues for developing novel chemotherapeutics.
Previously this team found a potential inhibitor (AOH1160) of caPCNA but it lacked suitable metabolic properties. Now they identified an analog of AOH1160, AOH1996 which can an suppress tumour growth as a monotherapy or combination treatment in cell and animal models without resulting in toxicity. The investigational chemotherapeutic is currently in a Phase 1 clinical trial in humans.
The team tested AOH1996 in normal cells and over 70 (cancer) cell lines. They found that AOH1996 selectively killed cancer cells, with a median concentration of about 300 nM for 50% growth inhibition. AOH1996 was not significantly toxic to non-malignant cells, even up to 10 µM. It induced cell cycle changes (G2/M or S phase arrest) and apoptosis in cancer cells but not non-malignant cells. AOH1996's half-life increased by approximately 27% relative to that of AOH1160 in oral pharmacokinetic studies in mice.
PS: Hope this will at least pave the way for the long sought miracle cancer pill that everybody was looking for.
Also if you have missed my earlier post, the Japanese alternative
https://elakiri.com/threads/japanes...-types-of-cancer-targeted-α-particle.2112231/
Scientists at a leading US hospital have developed a “cancer-killing pill” that kills solid tumours through “targeted chemotherapy.” Likened to a “snowstorm that closes a key airline hub, shutting down all flights in and out only in planes carrying cancer cells”, the protein was developed by a research team at the City of Hope, one of the largest cancer research and treatment organisations in the US.
Developed over the last two decades, it has shown to be effective in preclinical research treating breast, prostate, brain, ovarian, cervical, skin and lung cancers. The study, has tested the protein across over 70 cancer cell lines.
Background -
PCNA - Proliferating Cell Nuclear Antigen plays an essential role in nucleic acid metabolism as a component of the replication and repair machinery. This toroidal-shaped protein encircles DNA and can slide bidirectionally along the duplex. It has been historically used as a marker for tumor progression. DNA replication stress is a key hallmark of cancer cells that have been exploited as a therapeutic strategy to induce further DNA damage leading to catastrophic consequences for cancer cells. Thus, PCNA represents a major anti-cancer target, given its role in DNA replication/repair. Besides, discovering a distinct cancer-associated PCNA isoform (caPCNA) has opened new avenues for developing novel chemotherapeutics.
Previously this team found a potential inhibitor (AOH1160) of caPCNA but it lacked suitable metabolic properties. Now they identified an analog of AOH1160, AOH1996 which can an suppress tumour growth as a monotherapy or combination treatment in cell and animal models without resulting in toxicity. The investigational chemotherapeutic is currently in a Phase 1 clinical trial in humans.
The team tested AOH1996 in normal cells and over 70 (cancer) cell lines. They found that AOH1996 selectively killed cancer cells, with a median concentration of about 300 nM for 50% growth inhibition. AOH1996 was not significantly toxic to non-malignant cells, even up to 10 µM. It induced cell cycle changes (G2/M or S phase arrest) and apoptosis in cancer cells but not non-malignant cells. AOH1996's half-life increased by approximately 27% relative to that of AOH1160 in oral pharmacokinetic studies in mice.
PS: Hope this will at least pave the way for the long sought miracle cancer pill that everybody was looking for.
Also if you have missed my earlier post, the Japanese alternative
https://elakiri.com/threads/japanes...-types-of-cancer-targeted-α-particle.2112231/
Chemotheraphy වලදි දෙන drugs වලට, පිළිකා සෛල ප්රතිරෝධයක් දක්වන්න sialic acid හේතු වෙනවා කියලත් මේ ළගදි හොයන් තිබ්බා. ඒ ගැනත් ඉස්සරහට වීඩියෝ එකක් කරන්න හිතාගෙන ඉන්නෙ. 
